Background: To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors.
introduction Medullary carcinomas are rare breast tumors that account for <5% of invasive breast carcinomas [1] [2] [3] . The diagnosis of medullary carcinoma is usually defined by histologic diagnostic criteria proposed by Ridolfi et al. [4] . These histopathologic features include: lymphoplasmacytic infiltration, noninvasive microscopic circumscription, syncytial growth pattern >75%, and grade 2 or 3 nuclei. Despite these well-defined morphological features, medullary tumor diagnoses have poor reproducibility. Although several simplified classifications of a medullary phenotype have been proposed in order to increase reproducibility, the Ridolfi criteria remain the most generally accepted [5, 6] . Results of gene expression profiling show that medullary carcinoma may be a subtype of basal breast cancers, and a more modern definition would consider immunohistochemical results indicating negative estrogen, progesterone, and HER2 receptors. However, positive estrogen receptors (ER) and progesterone receptors (PgR) have been reported in up to 30%-40% of cases, and HER2 overexpression in ∼10% of tumors diagnosed as medullary subtype [7] [8] [9] [10] [11] [12] [13] [14] , leaving the diagnosis of medullary breast cancer an area of controversy.
Data on the prognosis of medullary breast cancer are also conflicting. Some studies have indicated that this histologic type is associated with a favorable prognosis despite its association with biological features, which usually characterize a more aggressive subtype [2, 4, [15] [16] [17] [18] . Other studies do not confirm this observation and some report survival rates similar to the invasive ductal type 'not otherwise specified' (NOS) [19] [20] [21] [22] .
In order to clarify the prognosis of patients diagnosed with medullary breast carcinoma, we compared the clinicopathological features and outcomes of patients diagnosed with medullary carcinoma with those having invasive ductal tumors NOS. Data were obtained from 13 International Breast Cancer Study Group (IBCSG) trials conducted from 1978 through 1999. Recognizing the changing criteria over time, we defined two cohorts. The 'full cohort' includes the pathologist-determined histology without regard to any other tumor features, and the 'restricted cohort' is a more pure classification restricted to patients with ER-negative grade 3 tumors. In studies describing both ER and grade in medullary subtypes, all, or at least the vast majority, of the tumors were characterized as ER negative and of poor grade [9, 13, 23, 24] . Thus, we considered the classification using these additional features as more appropriate. We further limited the description of our restricted cohort according to ER status, since almost all ER-negative tumors are without PgR expression and PgR expression has only been described in a subset of reports [25] . In order to have the proper comparator group, we matched the full cohort to all invasive ductal tumors and the restricted cohort to the ER-negative, poor grade invasive ductal tumors. In each cohort, we identified patients as having tumor histology of medullary breast carcinoma or invasive ductal carcinoma NOS.
patients and methods patients
Among the 12 409 patients enrolled in 13 IBCSG trials (conducted from 1978 to 1999) [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] , 127 were recorded as having medullary invasive tumors, 8096 invasive ductal tumors NOS, and 4186 other tumor types (including atypical medullary) (supplemental Table S1 , available at Annals of Oncology online; Table 1 ). All 13 trials included patients with early breast cancer and studied the timing and duration of chemoendocrine treatments. Histology was determined by central pathology review of submitted hematoxylin-and eosin-stained slides in 11 of the 13 trials (trials I-V, VIII, IX, [11] [12] [13] [14] and by local review for the remaining two (trials VI and VII, n = 2687) where central review was not available. The 'full cohort' includes all patients recorded as either having medullary or ductal NOS invasive tumors. The 'restricted cohort' is a subset of the full cohort restricted to those with grade 3 and ER-negative tumors: 47 patients with medullary invasive tumors and 1407 with invasive ductal NOS tumors (supplemental Figure S1 , available at Annals of Oncology online).
Patients with medullary and invasive ductal tumors were compared within the two defined cohorts with regard to age at diagnosis, menopausal status, local and systemic treatment, nodal status, tumor size, peritumoral vessel invasion (PVI), grade, and hormone receptor status.
The trials were conducted according to good clinical practice and in accordance with human investigation laws in the participating countries at the time of patient enrollment.
statistical methods
For the 13 trials, the protocol-defined primary end point was disease-free survival (DFS), defined as the time from randomization to the first occurrence of a breast event (local, regional, distant recurrence; contralateral breast event), a second (non-breast) malignancy, or a death before a cancer event. For this report with long-term follow-up, the more relevant end points used were distant recurrence-free interval (DRFI) and overall survival (OS). DRFI was defined as the time from randomization to first distant recurrence. Local and regional recurrences, contralateral breast and second non-breast events were ignored and follow-up continued until the first distant recurrence. Deaths without distant recurrences were censored. OS was defined as the time from randomization to death. DFRI and OS were presented using Kaplan-Meier curves. Log-rank P values of DFRI and OS were stratified by pathologist. There were four strata: one for each of the three central laboratories (the central laboratory changed three times over the 20-year period covered by these trials) and one strata for trials VI and VII (trials without central pathologic review). Competing risk regression models [39] were used to account for the competing risk of distant breast cancer events with other DFS events (i.e. local and regional results
patient and tumor characteristics
The median follow-up for both the full and the restricted cohorts was 14 years. In both cohorts, medullary and ductal carcinomas differed in their presentation of tumor characteristics: nodal status, tumor size, grade, PVI, and hormone receptor status, with medullary tumors being associated with less favorable prognostic features with the single exception that medullary tumors were less likely to have PVI ( Table 2 ). The majority of patients had some type of adjuvant systemic treatment: 67% of medullary cases and 77% of ductal cases in the full cohort received chemotherapy, and corresponding numbers in the restricted cohort were 68% versus 84% (Table 2) . Of the 127 medullary cases in the full cohort, 64 were enrolled in trials with a chemotherapy randomization and 34 were assigned chemotherapy; corresponding numbers for the restricted cohort were 26 randomized and 14 assigned chemotherapy.
sites of first DFS event
Patients with ductal tumors had more local and distant sites of first DFS event, whereas those with medullary tumors had more second non-breast malignancies and deaths without prior cancer event (Table 3) . These observations were similar in the two cohorts. 
Annals of Oncology original articles
The Kaplan-Meier curves in the full cohort show that the two histologic types had similar DRFI for the first 4 years, but thereafter, the curves split with consistently better outcome for the medullary subtype and a statistically significant overall DRFI [stratified log-rank test hazard ratio (HR) medullary/ductal = 0.52, 95% confidence interval (CI) = 0.36-0.75, P = 0.0005; Table 4 , Figure 1A ]. An even more pronounced difference was observed in the restricted cohort (DRFI HR medullary/ductal = 0.24, 95% CI = 0.10-0.58, P = 0.002; Table 4 , Figure 1B ) with the Kaplan-Meier curves diverging earlier. We note that because the hazards are not proportional, original articles Annals of Oncology the hazard rates are not constant over time. Therefore, the hazard rates reported represent an average over the entire follow-up period and the P values reflect the statistical significance of these HRs. In any case, the overall outcome for the medullary cohort is superior to that of the ductal cases. When the two subtypes were compared according to nodal status, similar results were observed in node-negative and node-positive subgroups, although the differences were statistically significant only among the patients with nodepositive disease. DRFI was significantly better for medullary tumors in both cohorts both with and without adjuvant chemotherapy (Table 4) . Among medullary cases in the full cohort, 10 of 34 randomly assigned chemotherapy had a distant recurrence compared with 7 of 34 not assigned chemotherapy; corresponding numbers for the restricted cohort were 2 of 14 compared with 1 of 12.
Comparisons between medullary and invasive ductal cohorts in terms of DFS were similar to those based on DRFI (data not shown).
overall survival
There also was a statistically significant difference in OS between the tumor histologic types for both the full cohort (OS HR medullary/ductal = 0.75, 95% CI = 0.58-0.97, P = 0.03; Table 4 , Figure 1C ) and for the restricted cohort (OS HR medullary/ductal = 0.55, 95% CI = 0.34-0.89, P = 0.01; Table 4 , Figure 1D ). When patients with medullary tumors were compared with those with ductal tumors in subgroups defined by nodal status, the OS for the medullary category was better in all cases, significantly so for the node-positive cohort (Table 4) . When negative PgR status was added to the characterization of the restricted medullary cohort, the outcome did not change (data not shown).
competing risks
A secondary analysis was carried out focusing on the competing risk of distant breast cancer events with non-distant DFS events. While the competing risk curves for the full cohort were nonproportional (i.e. the curves cross) (Figure 2A ), the curves restricted to patients with ER-negative grade 3 tumors were approximately proportional ( Figure 2B ). The result of the competing risk modeling in this restricted cohort indicated that medullary tumors had a significantly better prognosis than ductal carcinoma (HR medullary/ductal = 0.32, 95% CI = 0.13-0.78, P = 0.01). The result did not change after controlling for nodal status and tumor size (HR medullary/ductal = 0.32, 95% CI = 0.13-0.78, P = 0.01).
discussion
In our analysis of 12 409 patients, we identified only 127 (1.0%) medullary carcinomas, a frequency similar or slightly lower than in other published reports [1] [2] [3] . In both the full cohort and the restricted cohort, patients with medullary carcinomas had better outcomes overall compared with patients with invasive ductal carcinomas, despite medullary tumors being associated with biological features usually considered unfavorable. In fact, the 14-year DRFI of 89% in the restricted cohort of ER-negative grade 3 tumors was surprisingly good in this supposedly poor prognostic population. Our results thus confirm other reports that observed a superior outcome of tumors with medullary histology compared with invasive ductal tumors [2, 4, [15] [16] [17] [18] .
In subgroups defined by nodal status, a reduction in risk of distant recurrence for medullary cancers was observed for both node-negative and node-positive groups, although the differences were only statistically significant in the nodepositive group. The lack of significance in the node-negative (9) 749 (29) 7 (6) 91 (15) Second primary non-breast 12 (9) 362 (4) 3 (6) 49 (3) Death without prior cancer event 11 (9) 360 (4) 3 (6) 39 ( group may be due to the smaller number of cases, as several other reports describe better outcomes for medullary tumors irrespective of the nodal status [4, 13] . The lower risks of distant recurrence and death for medullary tumors compared with invasive ductal carcinomas were seen irrespective of the application of adjuvant chemotherapy. However, our data do not permit reliable conclusions regarding the role of adjuvant chemotherapy for patients with medullary tumors. Although patients with medullary tumors appear to have a relatively good prognosis even without chemotherapy, those with invasive ductal disease also have a better outcome without chemotherapy, indicating a selection bias to enroll patients with better prognosis in trials with a no chemotherapy option. Chemotherapy was a randomized option for very few patients with medullary tumors. Furthermore, several different chemotherapy regimens were given with or without endocrine therapy without considering ER status in the earlier trials. Thus, because the role of chemotherapy for medullary carcinomas in the restricted cohort is less certain than for invasive ductal carcinomas, further studies are needed to clarify this issue.
In our study, we were able to report on the sites of first recurrences, a feature not commonly reported by others. The majority of first recurrences were distant and we found that both local relapse and distant relapse were less frequently observed in the medullary type than in the invasive ductal type in both cohorts.
Although the main conclusions were similar in the full and restricted cohorts (i.e. improved outcome and association with poorer disease characteristics), we found differences between the two cohorts. The reduction in the risk of a distant recurrence in medullary tumors compared with invasive ductal Log-rank P values are stratified by pathologist review. DRFI, distant recurrence-free interval; CI, confidence interval; HR, hazard ratio; OS, overall survival; SE, standard error.
Annals of Oncology original articles
was higher in the restricted cohort (76%) than in the full cohort (48%). In the full cohort, the incidence of distant recurrence separated after 4 years, with few events occurring thereafter in the medullary group, whereas events in the invasive ductal group continued to be observed beyond 4 years. In the restricted cohort, the separation of events occurred earlier and after 4 years, there were very few distant recurrences in either the medullary or invasive ductal (G3, ER −) groups. The distribution of events over time is typical for ER-negative tumors and thus not surprising [40] . Nevertheless, there was a substantial advantage in the control of distant recurrence in the medullary type during the first 5 years after diagnosis, which persisted over time. These outcome distinctions between the two cohorts, with much clearer differences in the restricted group compared with its control group, support the suggestion that the definition of the medullary subtype seems to be most informative when restricted to ER-negative and poor grade tumors. In addition, the pattern of relapse occurring almost exclusively in the first 4 years in the restricted cohort further confirms this view.
These observations support recent reports linking the medullary tumors to myoepithelial features and the basal-like phenotype [14, 23, 41, 42] , which in most cases is immunohistochemically characterized by negative expression of ER, PgR, and HER2 (triple-negative tumors). Interestingly, microarray-based analyses showed that medullary carcinomas and invasive ductal tumors with a basal-like phenotype have distinct molecular characteristics [9, 23] even though they share similar biological features. In medullary breast cancer, genes involved in T h 1 immune response including interleukins, interferon regulatory factors, and T h 1 cytokines and genes related to the apoptosis pathway were upregulated. By contrast, genes involved in the remodeling of the cytoskeleton and genes associated with cell invasiveness were downregulated in medullary carcinomas [43] . These different molecular characteristics may account for the favorable outcome of medullary carcinomas and suggest that the group of basal-like tumors constitutes a heterogeneous group of carcinomas.
In conclusion, our analysis, based on a compilation of data from 13 trials conducted by a single cooperative group, demonstrates an improved outcome for patients with medullary breast carcinomas compared with invasive ductal carcinomas despite the former's unfavorable biologic features. These differences in outcome were most pronounced within the restricted cohort confined to patients with ER-negative grade 3 tumors and we suggest that lack of ER expression and poor grade should be part of the definition of medullary breast cancer. The definition of medullary subtype used in our restricted cohort does not include information on the HER2 status. However, as most medullary cancers lack HER2 overexpression/amplification, our conclusions would most likely not change if HER2 was known. Currently, ER-negative and in particular triple-negative tumors (used as surrogate for basal-like phenotype even though not completely concordant) will be treated on average with more intensive chemotherapy due to their prognosis and the observation that these tumors are more sensitive to chemotherapy than others [44, 45] . However, the favorable prognosis of medullary tumors and the different molecular pattern of these tumors, compared with others linked to the basal-like phenotype, raise questions about this treatment approach. Clinical data are lacking on the efficacy of adjuvant chemotherapy in this patient population and whether less adjuvant treatment should be given is still an area of controversy. The NCCN guidelines recommend to treat early medullary cancers as other infiltrating ductal tumors [46] , whereas the St Gallen Consensus recommendations suggest that medullary carcinomas may not require adjuvant cytotoxics if node-negative [47] . Based on the excellent 14-year DRFI in the medullary-restricted cohort, our data support this recommendation. Thus, we suggest that considering the histologic subtype may be helpful when deciding the appropriate adjuvant treatment assuming that the breast tumor is reliably classified as a medullary carcinoma. Lessons learned from rare tumors will improve our understanding of the biology of breast cancer and may help in further refinement and individualizing adjuvant treatment.
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